Pathos AI is acquiring Rain Oncology for $1.16 in cash per share plus a non-tradable contingent value right for potential cash payments of up to $0.17 per share, just a few months after investment group Tang Capital Management’s takeover bid failed. Rain will operate as a subsidiary of Pathos, with the acquisition expected to close in January, though the offer depends on several conditions, including the availability of at least $49.6 million in cash and cash equivalents. Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
BECOME A PREMIUM SUBSCRIBER